U.S. Supreme Court Put An End To Bristol-Myers Squibb Hepatitis B Case

U.S. Supreme Court Put An End To Bristol-Myers Squibb Hepatitis B Case

Last Monday the U.S. Supreme Court definitely bars Bristol-Myers Squibb Co’s way to restore patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers’ challenge to an appeals court ruling in favor of rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent. In a June 2014 ruling, the U.S. Court of Appeals for the Federal Circuit upheld the federal Delaware court’s conclusion that the patent was invalid. The case is Bristol-Myers v. Teva, U.S. Supreme Court, No. 14-886. Teva announced last September that it was launching its generic version of the drug